Vitamin D Test — Purpose, Procedure & Normal Values | MyMedicPlus

The vitamin D test measures the serum concentration of 25-hydroxyvitamin D (25-OHD, also called calcidiol) — the major circulating storage form of vitamin D and the most reliable and clinically accepted indicator of overall vitamin D status in the body. Vitamin D exists in two principal dietary and supplemental forms: vitamin D3 (cholecalciferol), synthesised in the skin from 7-dehydrocholesterol under the action of ultraviolet B (UVB) radiation and also found in oily fish, egg yolks, and fortified foods; and vitamin D2 (ergocalciferol), derived from plant and fungal sources. Both forms are hydroxylated in the liver by 25-hydroxylase to produce 25-OHD, which is then converted to the biologically active form, 1,25-dihydroxyvitamin D (calcitriol), primarily in the kidneys by 1-alpha-hydroxylase. Vitamin D's classical actions are essential for intestinal calcium and phosphate absorption (60–80% of dietary calcium absorption depends on adequate vitamin D), bone mineralisation and remodelling (deficiency in children causes rickets; in adults, osteomalacia — softening and painful bones), parathyroid hormone suppression (preventing secondary hyperparathyroidism), and neuromuscular function. Vitamin D receptors are also expressed widely in immune cells, cardiovascular tissue, and various organ systems, suggesting broader physiological roles that are still under active investigation.

The vitamin D test is ordered for individuals in at-risk groups with a clinical indication, rather than for routine population-wide screening in healthy individuals. At-risk populations in whom testing is clinically appropriate include: individuals with limited sun exposure — indoor workers, office workers, people who regularly wear sun-protective clothing or veil for cultural or religious reasons, housebound or institutionalised elderly patients, and people living at northern or southern latitudes (above 35 degrees from the equator) where UVB intensity is insufficient for cutaneous synthesis for much of the year. People with darker skin phototypes (Fitzpatrick types IV–VI) require up to 3–6 times longer sun exposure than lighter skin types for equivalent vitamin D synthesis, due to higher melanin content. Obese individuals (BMI above 30) — vitamin D3 is sequestered in adipose tissue, reducing its bioavailability. Patients with malabsorption syndromes including coeliac disease, Crohn's disease, cystic fibrosis, and those who have undergone Roux-en-Y gastric bypass or biliopancreatic diversion. Patients with chronic kidney disease (impaired 1-alpha-hydroxylation in the kidney). Patients with confirmed osteoporosis or a history of fragility (low-trauma) fractures. Individuals taking medications that increase vitamin D catabolism: enzyme-inducing anticonvulsants (carbamazepine, phenytoin, phenobarbitone), rifampicin, and long-term glucocorticoids. Exclusively breastfed infants, whose breast milk contains inadequate vitamin D.

No fasting is required for a vitamin D test; the blood draw can take place at any time of day. Inform your doctor of the dose and frequency of any vitamin D supplements or multivitamins you take. If you are being monitored for vitamin D toxicity following high-dose supplementation (10,000 IU per day or more), the timing of supplementation relative to the blood draw does not significantly affect the measured 25-OHD level (unlike vitamins with shorter half-lives), because 25-OHD has a serum half-life of approximately 2–3 weeks. However, if you have recently started or stopped supplementation, notify the requesting clinician so the result can be interpreted in context. Seasonality significantly affects vitamin D levels in temperate climates — 25-OHD values typically decline from September to April in the Northern Hemisphere as UVB intensity decreases. Testing in late winter or early spring captures the seasonal nadir and most accurately identifies individuals who are genuinely deficient. Conversely, testing in August or September reflects peak summer sun exposure and may produce a false reassurance of adequacy in an individual who will become deficient by winter. The testing process and interpretation are identical for adults, children, and during pregnancy.

A phlebotomist draws 3–5 mL of venous blood from the antecubital fossa of the arm using a standard venepuncture technique. The blood is collected into a serum separator tube (gold-top) and allowed to clot for 20–30 minutes before centrifugation. The serum is analysed using one of two main methods: automated immunoassay platforms (chemiluminescent immunoassay CLIA, or enzyme-linked immunosorbent assay ELISA) — widely available, fast, and relatively inexpensive, but prone to cross-reactivity between D2 and D3 metabolites and variability between different assay manufacturers of 10–20%, meaning results from different laboratories are not always directly comparable; or liquid chromatography-tandem mass spectrometry (LC-MS/MS) — the gold standard reference method that separately measures D2 and D3 metabolites with high accuracy and precision and less inter-laboratory variability, though more expensive and less widely available. Because of platform-specific variability, serial monitoring in the same patient should ideally use the same laboratory, assay, and reference method to ensure meaningful comparison of results over time. The Vitamin D External Quality Assessment Scheme (DEQAS) internationally standardises vitamin D assays. Results are typically available within 1–3 working days.

Serum 25-hydroxyvitamin D (25-OHD) reference categories as defined by the Endocrine Society (widely used clinical thresholds): Severe deficiency: below 12 ng/mL (30 nmol/L) — high risk of rickets in children and osteomalacia in adults, symptomatic deficiency likely; Deficiency: below 20 ng/mL (50 nmol/L) — at risk of bone disease and negative effects on calcium metabolism; Insufficiency: 20–29 ng/mL (50–74 nmol/L) — potentially suboptimal for some physiological functions; Sufficiency: 30–100 ng/mL (75–250 nmol/L) — generally adequate for bone health and calcium homeostasis; Optimal target range: 40–60 ng/mL (100–150 nmol/L) — achieves maximal PTH suppression and calcium absorption in most guidelines; Toxicity risk: above 100 ng/mL (250 nmol/L) — risk of hypercalcaemia begins to emerge; Definite toxicity: above 150 ng/mL (375 nmol/L) — hypercalcaemia, hypercalciuria, and target organ damage are likely. Note: the UK NICE and NHS define deficiency below 25 nmol/L (approximately 10 ng/mL) as severe, and the Vitamin D Council and Grassroots Health define optimal levels at 40–80 ng/mL. Clinicians should apply the reference ranges provided by their specific laboratory alongside the clinical picture.

The blood draw is safe with minimal risk of bruising or haematoma. The main analytical limitation is significant inter-laboratory and inter-assay variability — serum 25-OHD results from different laboratories using different platforms can vary by 10–20% for the same sample, which has clinical implications when interpreting borderline results or changing laboratories during monitoring. The DEQAS programme works toward standardisation but variability remains a real-world challenge. The clinically meaningful thresholds for vitamin D sufficiency are genuinely debated in the medical literature. While bone health benefits of achieving 25-OHD above 20 ng/mL (50 nmol/L) are well-established, claims about vitamin D benefits for cancer prevention, cardiovascular disease, autoimmune conditions, respiratory infections, and dementia have not been consistently confirmed by large randomised controlled trials (including the VITAL trial) at supplementation doses that raise levels to 30–50 ng/mL. Observational studies showing associations between low vitamin D and poor health outcomes may reflect reverse causation (ill health reducing sun exposure and appetite) rather than a causal relationship. For these reasons, population-wide vitamin D screening in healthy adults without risk factors is not recommended by major guidelines. Testing is most valuable in the at-risk groups listed above, where deficiency is common and treatment clearly beneficial.